ART Advanced Research Technologies Inc.
TSX : ARA

ART Advanced Research Technologies Inc.

September 05, 2007 07:15 ET

ART Advanced Research Technologies Inc. and National Research Council of Canada Institute for Biological Sciences to Jointly Develop Commercial Applications for Optix

NRC Institute for Biological Sciences is collaborating with ART to develop state-of-the-art molecular imaging solutions for preclinical and clinical research

MONTREAL, QUEBEC--(Marketwire - Sept. 5, 2007) - ART Advanced Research Technologies Inc. ("ART") (TSX:ARA), a Canadian medical device company and a leader in optical molecular imaging products for the healthcare and pharmaceutical industries, today announced that a collaboration agreement has been signed with the National Research Council of Canada's Institute for Biological Sciences ("NRC-IBS") for the development of client-oriented diagnostic applications using the Company's proprietary time domain technology, in the emerging discipline of molecular imaging.

NRC-IBS and ART have agreed to establish a partnership consisting of service, research and development activities. In collaboration with NRC-IBS, new diagnostic applications of ART's time domain technology and equipment for use in disease models will be developed and adopted by ART for application notes.

"The NRC-IBS is very pleased to collaborate with ART for the development of better diagnostics using molecular imaging, which can help identify and characterize brain-specific targets, and develop improved therapies for neurodegenerative diseases affecting the aging population. Optical imaging-based approaches also promise to accelerate drug evaluation and shorten the time to their clinical application", said Dr. Abedelnasser Abulrob, Research Officer at the NRC-IBS. Dr. Abulrob recently participated in a webcast to the scientific research community, launching ART's new in vivo optical imager, Optix® MX2. During this webcast, Dr. Abulrob provided experimental examples from his own research on the capabilities of Optix's analytical software package, OptiView™. Dr. Abulrob's team has been using the Optix system for new applications of optical imaging and fluorescence lifetime, in addition to the evaluation of investigative drugs in stroke and Alzheimer's disease and brain cancer.

"The scientific exchange and collaboration between the NRC-IBS and ART has already proven beneficial for advancing both scientific discovery and technology development in the emerging field of molecular imaging. This collaboration agreement with the NRC-IBS creates new opportunities to respond to the challenges faced by our customers in drug development. Now, by contributing to enable novel Optix applications, the NRC will play an important role in advancing our plan to develop solutions for our clients and help them shorten the drug development cycle," said Mr. Sebastien Gignac, ART's President and CEO.

About the NRC-IBS

Recognized globally for research and innovation, the NRC is a leader in the development of an innovative, knowledge-based economy for Canada through science and technology. The NRC operates world-class research facilities, as well as information, technology and innovation support networks from coast to coast. Its outstanding people help turn ideas and knowledge into new products, processes and services, creating value for Canada. The NRC works hand in hand with partners from industry, government and universities to help ignite the spark of innovation in communities across the land and to give Canadian companies a competitive edge in today's marketplace (www.nrc-cnrc.gc.ca). With over 75 years of research excellence, the NRC Institute for Biological Sciences (NRC-IBS) consists of a team of leading life science researchers dedicated to spearheading the next breakthrough discoveries and technologies in neurobiology, immunobiology and glycobiology. Driven by these challenges, NRC-IBS is focused on innovative research of interest to the healthcare and pharmaceutical sectors.

About ART

ART Advanced Research Technologies Inc. is a leader in molecular imaging products for the healthcare and pharmaceutical industries. ART has developed products in medical imaging, medical diagnostics, disease research, and drug discovery with the goal of bringing new and better treatments to patients faster. Optix®, an optical molecular imaging device designed for monitoring physiological changes in living systems at the preclinical study phases of new drugs, is used by industry and academic leaders worldwide. SoftScan®, an optical medical imaging device, is designed to improve the diagnosis and treatment of breast cancer. ART is commercializing these products in a global strategic alliance with GE Healthcare, a world leader in mammography and imaging. Finally, the Fenestra® line of molecular imaging contrast products provide image enhancement for a wide range of preclinical Micro CT applications allowing scientists to see greater detail in their imaging studies, with potential extension into other major imaging modalities. ART's shares are listed on the TSX under the ticker symbol ARA. For more information on ART, visit our website at www.art.ca.

This press release may contain forward-looking statements subject to risks and uncertainties that would cause actual events to differ materially from expectations. These risks and uncertainties are described in the most recent Annual Information Form and the financial statements for the year ended December 31, 2006, available on SEDAR (www.sedar.com).

Contact Information

  • ART Advanced Research Technologies Inc.
    Jacques Bedard
    Chief Financial Officer
    jbedard@art.ca
    or
    ART Advanced Research Technologies Inc.
    Mario Khayat
    Vice President, Optical Products
    514-832-0777
    mkhayat@art.ca
    www.art.ca